|
|
|
|
LEADER |
01330nam a2200229 u 4500 |
001 |
EB002138223 |
003 |
EBX01000000000000001276350 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
230103 r ||| eng |
245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Ranolazine (Corzyna -- KYE pharmaceuticals Inc.)
|h Elektronische Ressource
|b indication: patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies
|
246 |
3 |
1 |
|a Ranolazine (Corzyna -- KYE pharmaceuticals Inc.)
|
250 |
|
|
|a Version: Final
|
260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c May 2021, 2021
|
300 |
|
|
|a 1 PDF file (7 pages)
|
710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a CADTH common drug review
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK583807
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a The CADTH Canadian Drug Expert Committee (CDEC) recommends that ranolazine not be reimbursed as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers
|